February 4, 2008 / 2:09 PM / 11 years ago

FDA staff cite safety concern with Lilly drug

WASHINGTON (Reuters) - Excessive sedation is a “serious safety concern” with an experimental, long-acting form of Eli Lilly and Co’s blockbuster Zyprexa schizophrenia drug, U.S. drug reviewers said in an analysis released on Monday.

Food and Drug Administration staff said the injectable formulation, called Zyprexa Adhera, was shown to be effective for acute and long-term treatment of schizophrenia.

The analysis was released ahead of a Wednesday meeting by a panel of outside advisers who will review the drug.

Reporting by Lisa Richwine, editing by Gerald E. McCormick

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below